Back

N-acetylcarnosine attenuates age-associated declines in multi-organ systems to improve survival

Miranda, E. R.; Shahtout, J. L.; Watanabe, S.; Spaas, J.; Milam, N. Y.; Neiswanger, G.; Werbner, B.; Stuart, D.; Mookherjee, S.; Wilson, J.; Judge, M.; Goh, I. Y.; Slater, T.; Gallop, M. R.; Hu, G.; Karasawa, T.; Landers, J. K.; Rainbow, B.; O'Connor, K. T.; Black, N. J.; Lan, H.; Nikolova, L. S.; Li, Y.; Davey, C. F.; Cox, J. E.; Boudina, S.; Karner, C. M.; Harasymowicz, N. S.; Ramkumar, N.; Symons, J. D.; Chaix, A.; Long, J. Z.; Drummond, M. J.; Funai, K.

2025-08-22 physiology
10.1101/2025.08.19.671148 bioRxiv
Show abstract

Histidine containing dipeptides (HCDs) such as N-acetylcarnosine are endogenous metabolites that are ergogenic and mitigate metabolic dysfunction. We previously demonstrated that short-term N-acetylcarnosine treatment is highly efficacious in protecting muscle atrophy induced by disuse. Here we demonstrate that a 6-months treatment of N-acetylcarnosine attenuates a broad spectrum of age-associated maladies and improved survival by [~]50% in female mice. A comprehensive survey of organ systems revealed that N-acetylcarnosine prevents decline in adiposity, diastolic function, vasodilation, muscle strength, and bone density. Together, N-acetylcarnosine substantially delays the onset of system-wide end-stage pathology to prolong lifespan. As an endogenously present metabolite, treatment with N-acetylcarnosine may be a safe and promising intervention to promote healthy aging in humans.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.